DALLAS – SWK Holdings Corporation (NASDAQ:SWKH), a specialty finance company focused on the life sciences sector, has announced several financial transactions and updates to its portfolio since September 30, 2024. With a market capitalization of $196 million and an impressive gross profit margin of 91%, InvestingPro data shows the company maintains strong financial health with a robust current ratio of 57.7. The company has engaged in new funding agreements, received repayments from various borrowers, and expanded existing credit facilities.
In a series of funding activities, SWK advanced $5.0 million to Journey Medical (TASE:) in November to support the launch of EmrosiTM and provided $0.6 million to Biotricity, obtaining 600,000 stock warrants. December saw SWK close an $8.0 million loan with Triple Ring Technologies and extend $2.5 million to SKNV and MedMinder, existing…
